Trade Amgen - AMGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.29 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023818% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001596% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 262.62 |
| Open | 260.32 |
| 1-Year Change | -9.47% |
| Day's Range | 258.66 - 261.22 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 30, 2024 | 259.21 | -1.89 | -0.72% | 261.10 | 261.40 | 258.41 |
| Dec 27, 2024 | 262.62 | 1.66 | 0.64% | 260.96 | 263.30 | 260.14 |
| Dec 26, 2024 | 262.72 | 1.71 | 0.66% | 261.01 | 264.58 | 260.62 |
| Dec 24, 2024 | 263.56 | 2.52 | 0.97% | 261.04 | 264.37 | 260.39 |
| Dec 23, 2024 | 263.33 | 1.22 | 0.47% | 262.11 | 264.36 | 260.82 |
| Dec 20, 2024 | 262.99 | -3.32 | -1.25% | 266.31 | 268.55 | 261.14 |
| Dec 19, 2024 | 261.02 | 3.12 | 1.21% | 257.90 | 261.62 | 252.98 |
| Dec 18, 2024 | 258.64 | -5.72 | -2.16% | 264.36 | 266.90 | 258.04 |
| Dec 17, 2024 | 265.87 | 2.17 | 0.82% | 263.70 | 270.14 | 263.32 |
| Dec 16, 2024 | 265.72 | -4.23 | -1.57% | 269.95 | 272.45 | 265.72 |
| Dec 13, 2024 | 270.30 | -1.15 | -0.42% | 271.45 | 273.80 | 269.96 |
| Dec 12, 2024 | 273.79 | 3.84 | 1.42% | 269.95 | 275.71 | 269.95 |
| Dec 11, 2024 | 273.27 | -1.63 | -0.59% | 274.90 | 276.20 | 270.49 |
| Dec 10, 2024 | 275.69 | -1.24 | -0.45% | 276.93 | 277.81 | 272.10 |
| Dec 9, 2024 | 277.45 | 6.17 | 2.27% | 271.28 | 279.74 | 271.28 |
| Dec 6, 2024 | 272.01 | -2.34 | -0.85% | 274.35 | 274.43 | 270.53 |
| Dec 5, 2024 | 274.21 | -1.16 | -0.42% | 275.37 | 278.88 | 272.99 |
| Dec 4, 2024 | 278.20 | 2.65 | 0.96% | 275.55 | 279.20 | 273.25 |
| Dec 3, 2024 | 278.17 | 1.61 | 0.58% | 276.56 | 281.18 | 276.10 |
| Dec 2, 2024 | 277.97 | -2.83 | -1.01% | 280.80 | 281.16 | 276.70 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Amgen Company profile
About Amgen, Inc.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Amgen, Inc. revenues increased 2% to $25.98B. Net income decreased 19% to $5.89B. Revenues reflect Other revenues segment increase of 42% to $1.68B, Prolia segment increase of 18% to $3.25B, ROW segment increase of 12% to $7.01B, Other revenues segment increase of 42% to $1.68B. Net income was offset by Research and development increase of 15% to $4.82B (expense), Other increase of 3% to $194M (expense).
Equity composition
Common Stock $.0001 Par, 4/11, 2.75B auth., 929,730,507 issd. Insiders own 0.12% . IPO 5/87, 2M shares @ $34 by Paine Webber. 9/91, 3-for-1 split; 11/99, 3/99, 8/95, 7/90, 2-for-1 splits. 7/02, Company acquired Immunex Corp. @ $4.50/share and 0.44 shs. (242,916,735 shs. issd.).
| Industry: | Pharmaceuticals (NEC) |
One Amgen Center Drive
THOUSAND OAKS
CALIFORNIA 91320-1799
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com